Wall Street brokerages forecast that Immunomedics, Inc. (NASDAQ:IMMU) will report ($0.13) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Immunomedics’ earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.21). Immunomedics posted earnings per share of ($0.22) in the same quarter last year, which would suggest a positive year-over-year growth rate of 40.9%. The firm is expected to issue its next earnings report on Wednesday, May 9th.
On average, analysts expect that Immunomedics will report full-year earnings of ($0.96) per share for the current year, with EPS estimates ranging from ($1.07) to ($0.85). For the next financial year, analysts forecast that the firm will post earnings of ($0.23) per share, with EPS estimates ranging from ($0.96) to $0.50. Zacks’ EPS calculations are a mean average based on a survey of research firms that that provide coverage for Immunomedics.
Immunomedics (NASDAQ:IMMU) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.09). The firm had revenue of $0.60 million during the quarter, compared to the consensus estimate of $0.90 million.
In other Immunomedics news, Director David M. Goldenberg sold 20,000 shares of the business’s stock in a transaction dated Wednesday, March 7th. The stock was sold at an average price of $17.50, for a total transaction of $350,000.00. Following the completion of the sale, the director now owns 1,774,285 shares of the company’s stock, valued at $31,049,987.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David M. Goldenberg sold 17,729 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $17.09, for a total value of $302,988.61. Following the sale, the director now directly owns 1,774,285 shares of the company’s stock, valued at approximately $30,322,530.65. The disclosure for this sale can be found here. In the last ninety days, insiders sold 77,729 shares of company stock valued at $1,342,589. Company insiders own 14.80% of the company’s stock.
A number of hedge funds have recently bought and sold shares of IMMU. BlackRock Inc. grew its stake in Immunomedics by 8.8% during the fourth quarter. BlackRock Inc. now owns 9,064,259 shares of the biopharmaceutical company’s stock valued at $146,478,000 after acquiring an additional 736,608 shares in the last quarter. ArrowMark Colorado Holdings LLC lifted its stake in shares of Immunomedics by 48.5% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 5,225,124 shares of the biopharmaceutical company’s stock worth $84,438,000 after purchasing an additional 1,705,624 shares during the period. Palo Alto Investors LLC lifted its stake in shares of Immunomedics by 58.6% in the 4th quarter. Palo Alto Investors LLC now owns 4,774,261 shares of the biopharmaceutical company’s stock worth $77,152,000 after purchasing an additional 1,763,795 shares during the period. Jennison Associates LLC lifted its stake in shares of Immunomedics by 1.1% in the 4th quarter. Jennison Associates LLC now owns 1,830,914 shares of the biopharmaceutical company’s stock worth $29,588,000 after purchasing an additional 19,195 shares during the period. Finally, Victory Capital Management Inc. bought a new position in shares of Immunomedics in the 4th quarter worth approximately $17,941,000. 74.52% of the stock is owned by hedge funds and other institutional investors.
Immunomedics (NASDAQ IMMU) traded down $0.74 during midday trading on Wednesday, hitting $16.20. The stock had a trading volume of 2,768,856 shares, compared to its average volume of 2,317,745. Immunomedics has a 12 month low of $5.00 and a 12 month high of $18.93. The firm has a market capitalization of $2,470.00, a PE ratio of -8.71 and a beta of 1.48. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.26 and a current ratio of 1.26.
ILLEGAL ACTIVITY NOTICE: “Analysts Expect Immunomedics, Inc. (IMMU) to Announce -$0.13 EPS” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/03/14/analysts-expect-immunomedics-inc-immu-to-announce-0-13-eps.html.
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.